SCHEMBL8377992

SCHEMBL8377992

O=C1CN(C2(N3CC(=O)NC(=O)C3)CC2)CC(=O)N1

nearest known ligand 0.42

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
TOP2A P11388 3/20 0.42
TOP2B Q02880 3/20 0.42
ALDH1A1 P00352 1/20 0.42
MAPT P10636 1/20 0.42
TDP1 Q9NUW8 1/20 0.42
CRBN Q96SW2 4/20 0.40
PTGS1 P23219 2/20 0.34
LMNA P02545 1/20 0.34
PKM P14618 1/20 0.31
KDM4E B2RXH2 1/20 0.30
L3MBTL1 Q9Y468 1/20 0.30
CYP1A2 P05177 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1101973 0.65
SCHEMBL728996 0.63 TOP2A (0.50) TOP2ATOP2BALDH1A1MAPTTDP1
SCHEMBL9139881 0.59 TOP2A (0.41) TOP2ATOP2BALDH1A1MAPTTDP1
SCHEMBL4788784 0.59 TOP2A (0.41) TOP2ATOP2BALDH1A1MAPTTDP1
SCHEMBL16349791 0.59 TOP2A (0.52) TOP2ATOP2BALDH1A1MAPTTDP1
SCHEMBL4788789 0.59 TOP2A (0.41) TOP2ATOP2BALDH1A1MAPTTDP1
Icrf-193 SCHEMBL14006976 0.59 TOP2A (1.00) TOP2ATOP2BALDH1A1MAPTTDP1
SCHEMBL9752550 0.59 TOP2A (0.47) TOP2ATOP2BALDH1A1MAPTTDP1
SCHEMBL17716288 0.59 TOP2A (0.46) TOP2ATOP2BALDH1A1MAPTTDP1
SCHEMBL15548784 0.59 TOP2A (0.47) TOP2ATOP2BALDH1A1MAPTTDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-5866570-A Treatment of vascular leakage and related syndrome such as septic shock by administration of metalloproteinase inhibitors WISCONSIN ALUMNI RESEARCH FOUNDATION (US) 1999-02-02 US disclosed
EP-0642353-A1 TREATMENT OF VASCULAR LEAKAGE SYNDROME AND COLLAGENASE INDUCED DISEASE BY ADMINISTRATION OF MATRIX METALLOPROTEINASE INHIBITORS ONCOLOGIX, INC. (US) 1995-03-15 EP disclosed
WO-1993023075-A1 TREATMENT OF VASCULAR LEAKAGE SYNDROME AND COLLAGENASE INDUCED DISEASE BY ADMINISTRATION OF MATRIX METALLOPROTEINASE INHIBITORS ONCOLOGIX, INC. (US) 1993-11-25 WO disclosed